Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Kniepeiss, D; Iberer, F; Grasser, B; Schaffellner, S; Tscheliessnigg, KH.
Sirolimus and mycophenolate mofetil after liver transplantation.
Transpl Int. 2003; 16(7):504-509
Doi: 10.1007/s00147-003-0579-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kniepeiss Daniela
- Co-Autor*innen der Med Uni Graz
- Iberer Florian
- Schaffellner Silvia
- Tscheliessnigg Karlheinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Since the approval of sirolimus (SRL) as an immunosuppressive agent in renal transplantation, several liver transplant centres have introduced this agent to the immunosuppression regimen. We present here a retrospective follow-up study of late conversion to sirolimus and mycophenolate mofetil (MMF) as immunosuppressive agents after liver transplantation (LTX). From July 2001 to March 2002, seven liver transplant recipients (three female, 59 (41-66) years old) were enrolled in this study. Indications for liver transplantation were hepatitis B and/or hepatitis C (three), alcohol-induced cirrhosis (three) and Wilson's syndrome (hepatolenticular degeneration) (one). LTX was performed by standard (four) or piggy-back (three) technique. The switch to SRL was performed 62 (37-118) months after LTX; the reasons for the switch from cyclosporine or tacrolimus to SRL were renal (six) or neurological (one) impairment. As immunosuppressive therapy, SRL at trough levels of 4-10 ng/ml and MMF at trough levels of approximately 1 micro g/ml were administered. Mean follow-up time under SRL per patient was 137 (26-258 days). Patient and graft survival was 100% during SRL therapy, and there were neither rejection episodes nor infections. Renal function improved in five of the six patients (83.3%) whom we had switched to SRL due to renal impairment. In the patient whom we switched to SRL due to neurological impairment, the neurological symptoms abated, and renal function improved. Side effects (hypertriglyceridaemia, hypercholesterolaemia, exanthema) became manifest in three patients (42.8%). Cessation of therapy due to side effects was necessary in two patients (exanthema: one, hypertriglyceridaemia: one). One patient refused to continue the therapy with SRL because he wanted tablets, and we only had SRL in fluid form. The data of our study suggest that SRL is a potent immunosuppressive agent of potential benefit in clinical LTX. SRL in combination with MMF provided sufficient immunosuppression of liver allografts in the late course after LTX. Side effects were reversible with dose reduction or cessation of therapy. We can thus conclude that SRL might offer an immunosuppressive therapy for patients with renal or neurological impairment after LTX.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Calcineurin - antagonists & inhibitors
- Cyclosporine - adverse effects
- Drug Therapy, Combination -
- Female -
- Humans -
- Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use
- Kidney - drug effects Kidney - physiopathology
- Liver Transplantation -
- Male -
- Middle Aged -
- Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use
- Postoperative Care -
- Retreatment -
- Retrospective Studies -
- Sirolimus - adverse effects Sirolimus - therapeutic use
- Tacrolimus - adverse effects
- Find related publications in this database (Keywords)
- liver transplantation
- immunosuppression
- sirolimus
- nephrotoxicity